Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Endometrial Neoplasms × ixabepilone × Clear all

Phase

Status

Unknown 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Sarcoma 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Prostatic Diseases 1 Pancreatic Neoplasms 1 Pain 1 Non-squamous Non-small Cell Lung Cancer 1 Neoplasms, Glandular and Epithelial 1 Lung Neoplasms 1 Liver Neoplasms 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Genital Neoplasms, Male 1 Genital Diseases, Male 1 Gallbladder Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Breast Neoplasms, Male 1 Bile Duct Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

pembrolizumab 6 Paclitaxel 6 Carboplatin 4 niraparib 3 Megestrol Acetate 3 rucaparib 2 iso-sulfan blue 2 copanlisib 2 Taxes 2 Nivolumab 2 Lymph Node Excision 2 Fulvestrant 2 Filgrastim 2 Doxorubicin 2 Cisplatin 2 tremelimumab 1 tislelizumab 1 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 sonidegib 1 ribociclib 1 olaparib 1 nicotinamide-beta-riboside 1 lenvatinib 1 ixabepilone 1 irosustat 1 gedatolisib 1 futibatinib 1 fludarabine 1 durvalumab 1 budigalimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00883116 2017-03-09

IXAMPLE2

R-Pharm

Phase 3 Terminated

551 enrolled 13 charts

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡